Biotherapy Immunotherapy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Biotherapy and immunotherapy represent one of the most transformative advances in cancer medicine of the past two decades. Rather than directly attacking tumour cells with cytotoxic agents like conventional chemotherapy, immunotherapy works by modulating the patient's own immune system — either releasing natural immune brakes that cancer cells exploit, or directly engineering immune cells to recognise and destroy cancer. The Nobel Prize in Physiology or Medicine was awarded in 2018 to James Allison and Tasuku Honjo for their discovery of immune checkpoint inhibition, the mechanism underlying the most widely used class of cancer immunotherapy.

The broad category of biotherapy encompasses several distinct mechanistic classes. Checkpoint inhibitors block the PD-1/PD-L1 and CTLA-4 pathways that cancer cells exploit to evade immune surveillance, effectively releasing the immune system's brakes and allowing T-cells to recognise and destroy tumour cells. Monoclonal antibodies target specific tumour surface antigens (such as HER2 in breast and gastric cancer, or CD20 in lymphoma), directing immune effector functions against cancer cells while sparing normal tissue. Cytokine therapies such as interleukin-2 (IL-2) and interferon-alpha enhance immune effector cell activation. Cancer vaccines (including tumour-associated antigen vaccines and personalised neoantigen vaccines) aim to generate tumour-specific immune responses. CAR-T cell therapy involves genetically engineering the patient's own T-cells ex vivo to express chimeric antigen receptors targeting specific tumour antigens before reinfusing them.

Immunotherapy is now approved for a growing number of tumour types and has produced durable complete remissions — something rarely achieved with chemotherapy — in a significant subset of patients with metastatic melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, and haematological malignancies. All immunotherapy decisions are made in the context of multidisciplinary tumour board discussions.

Checkpoint inhibitors (anti-PD-1: pembrolizumab, nivolumab; anti-PD-L1: atezolizumab, durvalumab; anti-CTLA-4: ipilimumab) have regulatory approval for melanoma (metastatic and adjuvant), non-small cell lung cancer (NSCLC), renal cell carcinoma, urothelial bladder cancer, head and neck squamous cell carcinoma, Hodgkin lymphoma, microsatellite instability-high (MSI-H) or mismatch repair deficient tumours across all solid tumour types (tumour-agnostic approval), hepatocellular carcinoma, cervical cancer, endometrial cancer, and triple-negative breast cancer among others.

Monoclonal antibody biotherapies include trastuzumab (Herceptin) for HER2-positive breast and gastric cancers; rituximab for B-cell non-Hodgkin lymphoma and CLL; bevacizumab (anti-VEGF) for colorectal, lung, and ovarian cancers; cetuximab and panitumumab for EGFR-expressing colorectal and head and neck cancers. CAR-T cell therapies are approved for relapsed/refractory B-cell acute lymphoblastic leukaemia, diffuse large B-cell lymphoma, mantle cell lymphoma, and multiple myeloma. Bispecific T-cell engagers (BiTEs) such as blinatumomab are used in ALL relapse. Each treatment requires biomarker testing to identify eligible patients.

Eligibility for immunotherapy is determined by cancer type, stage, biomarker expression status, prior treatment history, and performance status. For checkpoint inhibitors, tumour PD-L1 expression (measured by immunohistochemistry on biopsy tissue) predicts response likelihood in many cancer types — patients with high PD-L1 expression (TPS ≥50% in NSCLC) derive the greatest benefit. Tumour Mutational Burden (TMB) is an emerging biomarker predicting checkpoint inhibitor response across cancer types. MSI-H or dMMR status confers eligibility for pembrolizumab regardless of tumour origin (FDA tumour-agnostic approval). Performance status (ECOG 0–1) and absence of active autoimmune disease are important eligibility criteria, as immunotherapy can trigger immune-related adverse events (irAEs) particularly in patients with pre-existing autoimmunity.

CAR-T therapy candidates have relapsed or refractory haematological malignancies after at least two prior lines of therapy and must have adequate organ function and performance status to tolerate the conditioning chemotherapy preceding infusion. Patients on high-dose corticosteroids are generally not candidates for checkpoint inhibitors as steroids blunt immune activation. All candidates require comprehensive biomarker profiling, CT staging, and review by a multidisciplinary oncology team.

Checkpoint inhibitor immunotherapy is administered intravenously as monotherapy or combined with chemotherapy, targeted therapy, or another checkpoint inhibitor (dual checkpoint blockade). Treatment cycles are typically every 2, 3, or 6 weeks depending on the agent, and continue until disease progression, unacceptable toxicity, or completion of planned duration (typically 1–2 years for adjuvant settings). Pembrolizumab is now approved as first-line monotherapy for NSCLC with PD-L1 TPS ≥50%, melanoma, and MSI-H solid tumours, delivering overall survival benefits unprecedented in these indications.

CAR-T cell therapy involves leukapheresis (collection of the patient's T-cells), a manufacturing process of 2–4 weeks (during which bridging chemotherapy may be given to control disease), lymphodepleting conditioning chemotherapy (fludarabine and cyclophosphamide), and then CAR-T cell infusion, followed by intensive in-hospital monitoring for 7–14 days for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Personalised neoantigen vaccines, adoptive T-cell transfer, and tumour-infiltrating lymphocyte (TIL) therapies represent emerging approaches being evaluated in clinical trials. Combination strategies pairing checkpoint inhibitors with radiation, VEGF inhibitors, or targeted agents are the subject of hundreds of ongoing clinical trials.

Selecting the most appropriate Biotherapy Immunotherapy approach requires a structured assessment of patient-specific factors. The treating specialist evaluates disease severity, prior treatment history, comorbidities, and patient preferences before recommending a specific protocol. Combination approaches are often more effective than monotherapy — integrating pharmacological, procedural, or rehabilitative elements to address multiple disease mechanisms simultaneously. Dose or intensity is titrated incrementally based on clinical response, tolerability, and objective outcome measures. In patients with refractory disease or inadequate response to first-line protocols, escalation to higher-intensity or specialist-delivered treatment options is indicated. Multidisciplinary team (MDT) review ensures that surgical, medical, and allied health perspectives are integrated into the final management plan, particularly for complex or high-risk cases where multiple treatment pathways are viable and the risk-benefit balance requires careful deliberation.

Immunotherapy has produced historically unprecedented long-term remissions in cancer types previously associated with rapid mortality. In metastatic melanoma, combination ipilimumab plus nivolumab achieves 5-year survival rates of approximately 50% compared with median survival of under 12 months with chemotherapy in the pre-immunotherapy era. In NSCLC with high PD-L1 expression, pembrolizumab monotherapy achieves 5-year overall survival rates of approximately 25–30% versus less than 5% with historical chemotherapy for metastatic disease.

A small but meaningful proportion of patients — particularly those with very high PD-L1 or TMB, microsatellite instability, or specific tumour types — achieve durable complete remissions that persist years after treatment discontinuation. This 'tail of the survival curve' represents a qualitative difference from chemotherapy and has generated the concept of functional cure in oncology. CAR-T therapy achieves complete remission in approximately 70–90% of patients with relapsed B-ALL at the time of infusion, though maintaining long-term remission remains an ongoing challenge.

Immune-related adverse events (irAEs) are the principal toxicity of checkpoint inhibitor immunotherapy, resulting from non-specific immune system activation affecting normal tissues. Common irAEs include immune-mediated dermatitis (rash, pruritus — occurring in 30–50% of patients), colitis (diarrhoea, abdominal pain — 10–20%), hypothyroidism (15–20%), pneumonitis (2–5%), hepatitis (5–10%), and hypophysitis affecting the pituitary gland (1–5% with ipilimumab). Most irAEs are manageable with temporary treatment interruption and systemic corticosteroids. Severe grade 3–4 irAEs occur in approximately 15–20% of patients on combination checkpoint blockade and may require permanent treatment discontinuation and prolonged immunosuppression.

CAR-T therapy carries specific serious toxicities: cytokine release syndrome (CRS) — a systemic inflammatory response causing fever, hypotension, and hypoxia — occurs in approximately 40–90% of patients, is graded 1–4 in severity, and is managed with tocilizumab (IL-6 receptor blockade) and corticosteroids in severe cases. ICANS — immune effector cell-associated neurotoxicity syndrome — causes encephalopathy, aphasia, and in severe cases cerebral oedema, and requires specialist neurological management. Both toxicities require inpatient monitoring at certified CAR-T treatment centres.

Patients on checkpoint inhibitor immunotherapy are monitored throughout treatment with regular clinical assessment, liver function tests, thyroid function tests, cortisol and ACTH levels (to detect hypophysitis), chest X-ray or CT for pneumonitis, and skin examination at each cycle visit. Oncology nursing teams provide irAE education and ensure patients know to report new symptoms promptly between clinic visits.

Imaging response assessment (CT scan or PET-CT) is performed after every 2–4 treatment cycles to evaluate tumour response using RECIST 1.1 criteria. Pseudo-progression — transient tumour enlargement from immune infiltration before regression — can occur and must be distinguished from true progression with repeat imaging or biopsy. After completing planned treatment or achieving complete response, surveillance imaging is continued at 3–6 monthly intervals. Patients who develop immune-related endocrine toxicities (hypothyroidism, adrenal insufficiency, type 1 diabetes) require lifelong hormone replacement even after cancer treatment ends.

Immunotherapy agents are among the most expensive treatments in medicine. Annual costs of checkpoint inhibitor monotherapy (e.g., pembrolizumab) are approximately USD 150,000–200,000 per year in the United States; combination regimens cost USD 250,000–350,000 per year. CAR-T cell therapies are priced at USD 400,000–500,000 per infusion for a single course. These costs reflect the complexity of development and manufacturing and create significant access challenges globally.

Medical tourism for immunotherapy is primarily driven by regulatory differences and cost differentials for biosimilar monoclonal antibodies. In India, biosimilar trastuzumab (for HER2-positive breast cancer) costs approximately USD 200–400 per cycle versus USD 3,000–5,000 in the US — a saving of 90%. Biosimilar rituximab is similarly available at dramatically lower costs at Indian oncology centres. Full checkpoint inhibitor courses remain expensive globally, though Indian prices are 30–50% lower than US prices and several government programmes provide subsidised access. Thailand, Turkey, and Mexico also offer significantly lower immunotherapy costs. All treatment decisions should be made with accredited oncologists who have access to current molecular testing.

For each specific cancer indication, immunotherapy is positioned within a broader treatment landscape that includes surgery, conventional chemotherapy, radiation therapy, and targeted therapies (small molecule kinase inhibitors such as EGFR inhibitors, ALK inhibitors, BRAF/MEK inhibitors). The choice among these modalities depends on cancer type, molecular profile, stage, prior treatments, and patient performance status.

In many cancers where immunotherapy is now approved, it is used in combination with or sequentially after other modalities rather than as a standalone approach. For microsatellite-stable colorectal cancer (the majority of cases), checkpoint inhibitors are ineffective, and standard chemotherapy combinations (FOLFOX, FOLFIRI with bevacizumab or cetuximab) remain the backbone of treatment. Personalised oncology — matching each patient's cancer molecular profile to the optimal treatment — is the defining paradigm of modern oncology, and immunotherapy occupies an increasingly central position within this framework.